Literature DB >> 27920002

Decreased Skeletal Muscle Mass After Neoadjuvant Therapy Correlates with Poor Prognosis in Patients with Esophageal Cancer.

Jiajia Liu1, Satoru Motoyama2,3, Yusuke Sato2, Akiyuki Wakita2, Yuta Kawakita2, Hajime Saito2, Yoshihiro Minamiya2.   

Abstract

BACKGROUND: Loss of skeletal muscle is predictive of a poor prognosis in patients with various malignant lesions. Our aim was to determine whether changes in skeletal muscle after neo-adjuvant therapy (NAT) predict prognosis in patients with esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy. PATIENTS AND METHODS: The cross-sectional areas of the psoas muscles were measured on computed tomographic images collected at the initial visit, preoperatively and postoperatively in 84 patients. The psoas muscle index (PMI) was calculated by normalizing the cross-sectional areas to the patients' heights.
RESULTS: Low PMI at the initial visit was not associated with a poor prognosis. The majority of patients showed decreased PMI after NAT and surgery. The group in which the post-NAT PMI decreased had poorer overall survival than group without PMI decrease (p=0.025).
CONCLUSION: Decreased PMI correlates well with a poor prognosis in patients with ESCC. Changes in PMI over a period of time may have greater sensitivity when evaluating prognosis than the PMI at any single time point. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Skeletal muscle; esophageal cancer; neo-adjuvant therapy; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27920002     DOI: 10.21873/anticanres.11278

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

Review 1.  Chemotherapy-Induced Sarcopenia.

Authors:  Federico Bozzetti
Journal:  Curr Treat Options Oncol       Date:  2020-01-30

Review 2.  Development of selective androgen receptor modulators (SARMs).

Authors:  Ramesh Narayanan; Christopher C Coss; James T Dalton
Journal:  Mol Cell Endocrinol       Date:  2017-06-15       Impact factor: 4.102

3.  Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.

Authors:  Naoki Kamitani; Kazuhiro Migita; Sohei Matsumoto; Kohei Wakatsuki; Tomohiro Kunishige; Hiroshi Nakade; Shintaro Miyao; Masayuki Sho
Journal:  Surg Today       Date:  2019-07-15       Impact factor: 2.549

4.  Elevated Serum AA/EPA Ratio as a Predictor of Skeletal Muscle Depletion in Cachexic Patients with Advanced Gastro-intestinal Cancers.

Authors:  Moeko Kitagawa; Seiji Haji; Teruyoshi Amagai
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

5.  Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy.

Authors:  Sho Sato; Chikara Kunisaki; Hideaki Suematsu; Yusaku Tanaka; Hiroshi Miyamoto; Takashi Kosaka; Norio Yukawa; Kuniya Tanaka; Kei Sato; Hirotoshi Akiyama; Itaru Endo
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

Review 6.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

7.  Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.

Authors:  Yuta Kawakita; Satoru Motoyama; Yusuke Sato; Akiyuki Wakita; Yushi Nagaki; Kazuhiro Imai; Yoshihiro Minamiya
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

8.  Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.

Authors:  Tommi Järvinen; Ilkka Ilonen; Juha Kauppi; Jarmo Salo; Jari Räsänen
Journal:  World J Surg Oncol       Date:  2018-02-12       Impact factor: 2.754

9.  Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer.

Authors:  Han Gyul Yoon; Dongryul Oh; Yong Chan Ahn; Jae Myoung Noh; Hongryull Pyo; Won Kyung Cho; Yun Mi Song; Minsu Park; Na Young Hwang; Jong-Mu Sun; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

Review 10.  Immunometabolism: new insights and lessons from antigen-directed cellular immune responses.

Authors:  Renata Ramalho; Martin Rao; Chao Zhang; Chiara Agrati; Giuseppe Ippolito; Fu-Sheng Wang; Alimuddin Zumla; Markus Maeurer
Journal:  Semin Immunopathol       Date:  2020-06-09       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.